Overview

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.
Phase:
N/A
Details
Lead Sponsor:
Indiana University
Collaborator:
GlaxoSmithKline
Treatments:
Lapatinib